This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy
by Zacks Equity Research
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval
by Zacks Equity Research
Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.
Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
by Kinjel Shah
FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.
Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
by Zacks Equity Research
Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.
Novartis Announces New Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
by Zacks Equity Research
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
by Zacks Equity Research
Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.
Is Novartis (NVS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Biogen Stops Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
by Kinjel Shah
The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
by Zacks Equity Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
by Zacks Equity Research
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVS) Outperforming Other Medical Stocks This Year?
4 Big Drugmakers Boasting Impressive Oncology Pipelines
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe
by Zacks Equity Research
The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
Novartis Announces Positive Long-Term Data on Migraine Drug
by Zacks Equity Research
Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?
by Zacks Equity Research
Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.
FDA Grants Priority Review to Global Blood's SCD Candidate
by Zacks Equity Research
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
by Zacks Equity Research
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
by Kinjel Shah
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC
by Zacks Equity Research
AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Why Novartis (NVS) Stock Might be a Great Pick
by Zacks Equity Research
Novartis (NVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Novartis Inks Commercialization Deal for Tysabri Biosimilar
by Zacks Equity Research
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
Global Blood Focuses on Lead Candidate Amid Competition
by Zacks Equity Research
Global Blood (GBT) focuses on the development of its lead product candidate, voxelotor - an oral, once-daily treatment for SCD.